Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Net Income
Bottom-line profit after all expenses, interest, and taxes.
Entera Bio Ltd.NASDAQ: ENTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$3.51M, compared with -$2.57M a year earlier. Trailing-twelve-month net income was -$12.38M.
Context
- Net income amounted to 27235.7% of revenue in FY2025, up 21964.4 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$22.98M (-100.9%) for the fiscal year ending Dec 2026, a slowdown from the -19.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.51M-16.2% QoQ
- Last fiscal yearDec 2025
- -$11.44M-19.9% YoY
- LTMMar 2026
- -$12.38M-22.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -36.5% | -52.0% | -15.4 pp |
| 1 year | -19.9% | -100.9% | -81.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (11.44M) USD
- Year-over-year change
- -19.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.44M) | -19.9% |
| FY2024 | 2024-12-31 | (9.54M) | -7.3% |
| FY2023 | 2023-12-31 | (8.89M) | +32.0% |
| FY2022 | 2022-12-31 | (13.07M) | -7.3% |
| FY2021 | 2021-12-31 | (12.19M) | — |
Net Income vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's LTM Mar 2026 net income of -$12.38M is the 4th highest of the 10 companies compared; the peer median is -$46.9M.
- Its year-over-year change of -22.7% is the 7th highest of 10, against a peer median of +12.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.61M | +133.9% | — | 52.2% | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| LTM Apr 2026 | -$10.07M | +17.0% | — | — | |
| LTM Mar 2026 | -$12.38M | -22.7% | — | — | |
| LTM Mar 2026 | -$30.93M | -50.4% | — | — | |
| LTM Mar 2026 | -$46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | -$70.49M | +17.9% | — | 468.7% | |
| LTM Mar 2026 | -$84.93M | +12.0% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$106.93M | -82.4% | — | 892.4% |
| LTM Mar 2026 | -$113.28M | +2.6% | — | — | |
| Peer median (excluding ENTX) | -$46.9M | +12.0% | — | 468.7% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 571K | 134K | 0 | 181K | 42K |
| Cost of Revenue | 373K | 165K | 56K | 172K | 42K |
| Gross Profit | 198K | (31K) | (56K) | 9K | 0 |
| Gross Margin | 34.7% | -23.1% | — | 5.0% | 0.0% |
| Research & Development | 6.77M | 5.78M | 4.45M | 4.5M | 6M |
| Selling, General & Admin | 5.69M | 7.25M | 4.43M | 5.1M | 5.53M |
| Operating Expenses | 12.42M | 13.04M | 8.88M | 9.59M | 11.53M |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| EBITDA | (12.16M) | (12.87M) | (8.8M) | (9.48M) | (11.41M) |
| EBITDA Margin | -2130.3% | -9604.5% | — | -5238.1% | -27164.3% |
| Operating Income | (12.22M) | (13.07M) | (8.94M) | (9.59M) | (11.53M) |
| Operating Margin | -2139.6% | -9752.2% | — | -5295.6% | -27450.0% |
| Interest Income | 0 | 83K | 31K | 58K | 0 |
| Interest Expense | 29K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (29K) | 134K | 80K | 58K | 90K |
| Income Before Tax | (12.25M) | (12.93M) | (8.86M) | (9.53M) | (11.44M) |
| Pre-Tax Margin | -2144.7% | -9652.2% | — | -5263.5% | -27235.7% |
| Income Tax Expense | (59K) | 137K | 29K | 14K | 0 |
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Net Margin | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
| EPS (Basic) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| EPS (Diluted) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| Weighted Avg Shares | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
| Weighted Avg Shares (Diluted) | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.